$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2016 Q4 Form 10-Q Financial Statement

#000119312516764315 Filed on November 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.510M $3.320M $2.910M
YoY Change -39.69% 14.09% 26.52%
% of Gross Profit
Research & Development $1.330M $2.461M $2.864M
YoY Change -63.76% -14.07% 110.91%
% of Gross Profit
Depreciation & Amortization $170.0K $160.0K $160.0K
YoY Change 0.0% 0.0% -5.88%
% of Gross Profit
Operating Expenses $5.183M $5.777M $5.779M
YoY Change -46.36% -0.03% 51.05%
Operating Profit -$5.777M -$5.779M
YoY Change -0.03% 51.05%
Interest Expense $180.0K $340.0K $0.00
YoY Change 1700.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $182.0K -$99.00K -$1.000K
YoY Change 1554.55% 9800.0% -101.3%
Pretax Income -$5.000M -$5.880M -$5.780M
YoY Change -48.19% 1.73% 54.13%
Income Tax
% Of Pretax Income
Net Earnings -$5.001M -$5.876M -$5.780M
YoY Change -48.19% 1.66% 54.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$16.99K -$26.37K -$28.25K
COMMON SHARES
Basic Shares Outstanding 243.9M shares 212.8M shares 204.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.170M $5.180M $18.88M
YoY Change -91.75% -72.56% 6.25%
Cash & Equivalents $1.166M $5.178M $18.88M
Short-Term Investments
Other Short-Term Assets $360.6K $187.2K $1.066M
YoY Change 775.32% -82.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.826M $5.415M $19.95M
YoY Change -87.59% -72.86% 12.24%
LONG-TERM ASSETS
Property, Plant & Equipment $72.03K $75.22K $88.64K
YoY Change -15.4% -15.14% -7.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $27.00K $27.00K
YoY Change -100.0% 0.0% 0.0%
Total Long-Term Assets $3.785M $5.270M $6.654M
YoY Change -33.83% -20.8% 71.77%
TOTAL ASSETS
Total Short-Term Assets $1.826M $5.415M $19.95M
Total Long-Term Assets $3.785M $5.270M $6.654M
Total Assets $5.611M $10.69M $26.60M
YoY Change -72.55% -59.84% 22.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.920M $1.490M $970.0K
YoY Change 1.59% 53.61% 102.08%
Accrued Expenses $220.0K $550.0K $1.090M
YoY Change -90.18% -49.54% 172.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.142M $5.376M $2.075M
YoY Change -48.05% 159.12% 135.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.142M $5.376M $2.075M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.140M $5.380M $2.075M
YoY Change -48.09% 159.32% -1.6%
SHAREHOLDERS EQUITY
Retained Earnings -$205.2M -$200.2M -$171.1M
YoY Change 13.51% 16.99% 8.93%
Common Stock $364.8K $243.9K $204.6K
YoY Change 77.96% 19.18% 13.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.469M $5.310M $24.53M
YoY Change
Total Liabilities & Shareholders Equity $5.611M $10.69M $26.60M
YoY Change -72.55% -59.84% 22.9%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$5.001M -$5.876M -$5.780M
YoY Change -48.19% 1.66% 54.17%
Depreciation, Depletion And Amortization $170.0K $160.0K $160.0K
YoY Change 0.0% 0.0% -5.88%
Cash From Operating Activities -$4.020M -$5.000M -$4.230M
YoY Change -18.95% 18.2% 24.41%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0% -85.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0% -85.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.280M 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.020M -5.000M -4.230M
Cash From Investing Activities 0.000 0.000 -10.00K
Cash From Financing Activities 0.000 5.280M 0.000
Net Change In Cash -4.020M 280.0K -4.240M
YoY Change -14.47% -106.6% 1111.43%
FREE CASH FLOW
Cash From Operating Activities -$4.020M -$5.000M -$4.230M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow -$4.020M -$5.000M -$4.220M
YoY Change -18.95% 18.48% 26.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
59861601 shares
CY2015Q4 pvct Class Of Warrant Or Right Discounted Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightDiscountedExercisePriceOfWarrantsOrRights
0.50
CY2015Q4 pvct Class Of Warrant Or Right Cash Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCashExercisePriceOfWarrantsOrRights
0.85
CY2016Q2 pvct Number Of Shares Issuable On Exercises Of Warrants Issued
NumberOfSharesIssuableOnExercisesOfWarrantsIssued
51149594 shares
CY2016Q2 pvct Class Of Warrant Or Right Discounted Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightDiscountedExercisePriceOfWarrantsOrRights
0.75
CY2016Q2 pvct Class Of Warrant Or Right Cash Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCashExercisePriceOfWarrantsOrRights
0.85
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
243895352 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7798507 shares
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18883662
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.275
CY2016Q3 pvct Number Of Stockholders Who Did Not Receive Notification On Settlement
NumberOfStockholdersWhoDidNotReceiveNotificationOnSettlement
6300 Stockholders
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
460954
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
243895352 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
243895352 shares
CY2016Q3 us-gaap Assets
Assets
10685524
CY2016Q3 us-gaap Assets Current
AssetsCurrent
5415298
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5178076
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
243895
CY2016Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1486240
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
192000
CY2016Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
205288577
CY2016Q3 us-gaap Cumulative Dividends
CumulativeDividends
726989
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
3678989
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9306197
CY2016Q3 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
50000
CY2016Q3 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
683250
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
187222
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
18100 shares
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10685524
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2409248
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5375812
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
355232
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
18
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75219
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
5309712
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200222778
CY2016Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
2045789
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
18100 shares
CY2016Q3 pvct Litigation Settlement Remaining Reserve
LitigationSettlementRemainingReserve
870578
CY2016Q3 pvct Litigation Settlement Remaining Balance Due
LitigationSettlementRemainingBalanceDue
2125509
CY2016Q3 pvct Market Price Per Share Of Common Stock
MarketPricePerShareOfCommonStock
0.127
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
204979
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1887171
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
133282
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
196908112
CY2016Q3 pvct Warrant Liability
WarrantLiability
3342340
CY2016Q3 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
2075509
CY2016Q3 pvct Derivative Instruments Warrants
DerivativeInstrumentsWarrants
3342340
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17391601
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
451028
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204979100 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204979100 shares
CY2015Q4 us-gaap Assets
Assets
20439812
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14720094
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14178902
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8802857
CY2015Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
500000
CY2015Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
683250
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
41192
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20439812
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2912588
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4122871
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252418
CY2015Q4 us-gaap Litigation Reserve
LitigationReserve
227750
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
85145
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
16316941
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180796150
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1850000
CY2015Q4 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
2011735
CY2015Q4 pvct Number Of Shares Issuable On Exercises Of Warrants Issued
NumberOfSharesIssuableOnExercisesOfWarrantsIssued
59861601 shares
CY2016Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3899254
CY2016Q1 pvct Class Of Warrant Or Right Number Of Warrants Issued During Period
ClassOfWarrantOrRightNumberOfWarrantsIssuedDuringPeriod
7798507 shares
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
us-gaap Net Income Loss
NetIncomeLoss
-14850109
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-653228
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6139
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14850109
us-gaap Operating Income Loss
OperatingIncomeLoss
-14990841
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13944755
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
CY2016Q3 pvct Exercisable Warrants To Purchase Common Stock
ExercisableWarrantsToPurchaseCommonStock
24000000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1492061
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7453401
us-gaap Depreciation
Depreciation
9669
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
503340
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-136987
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
79476
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
685354
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
531991
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
87956
us-gaap Investment Income Interest
InvestmentIncomeInterest
3745
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12446555
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6139
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7537440
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
192604128 shares
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
136987
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
165439
pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
13653927
pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
290828
pvct Interest And Taxes
InterestAndTaxes
0
dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
2257432
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000315545
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9000826
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
31066
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12454661
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Depreciation
Depreciation
9926
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
503340
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
336649
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-336649
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-400931
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
146030
us-gaap Net Income Loss
NetIncomeLoss
-19426628
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-386226
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
711470
us-gaap Revenues
Revenues
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
161532
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22411049
us-gaap Operating Income Loss
OperatingIncomeLoss
-19329014
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8923570
us-gaap Investment Income Interest
InvestmentIncomeInterest
1985
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17924396
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <u>Estimates</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
pvct Increase Decrease In Accrued Settlement Expenses
IncreaseDecreaseInAccruedSettlementExpenses
-1850000
dei Trading Symbol
TradingSymbol
PVCT
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Monte Carlo valuation method
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6874353
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
213722977 shares
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
Preferred Stock and August 2016 Warrants were sold together at a price of $25.00 for a combination of one share of Preferred Stock and 100 August 2016 Warrants to purchase one share of common stock each
pvct Beneficial Conversion Feature In Preferred Stock
BeneficialConversionFeatureInPreferredStock
726989
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
336649
pvct Litigation Settlement Present Value Of Discount Remaining
LitigationSettlementPresentValueOfDiscountRemaining
133912
pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The remaining cash settlement amounts will continue to be repaid to the Company over a period of four years with the second payment due in total by October 2016 and the final payment is expected to be received by October 3, 2019. $150,000 was repaid by the Executives during the three months ended September 30, 2016, and a total of $450,000 was repaid for the nine months ended September 30, 2016. An additional $19,962 of the settlement discount was amortized as of September 30, 2016, and a total of $63,774 was amortized for the nine months ended September 30, 2016.
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
20163
pvct Warrants Expiration Date
WarrantsExpirationDate
2021-08-30
pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
19962
pvct Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3635040
pvct Warrant Incentive Expense
WarrantIncentiveExpense
2718407
pvct Interest And Taxes
InterestAndTaxes
0
pvct Litigation Settlement Amortization Amount
LitigationSettlementAmortizationAmount
63774
pvct Gross Proceeds From Sales Of Convertible Preferred Stock And Warrants
GrossProceedsFromSalesOfConvertiblePreferredStockAndWarrants
6000000
pvct Contractual Dividend On Preferred Stock
ContractualDividendOnPreferredStock
729989
pvct Issuance Inkind Of Preferred Stock Dividends
IssuanceInkindOfPreferredStockDividends
2257432
pvct Public Offering Issuance Expense
PublicOfferingIssuanceExpense
436248
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1632
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
3000 shares
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
3693898 shares
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53582
CY2015Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
100000 shares
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1161790 shares
CY2016Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
51745 shares
CY2016Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1048494 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3830000 shares
CY2016Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1757253 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2914375
CY2015Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
24262
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5780053
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5780053
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5778706
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1260
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2864331
CY2015Q3 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
78877 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
204610080 shares
CY2015Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
79500 shares
CY2015Q3 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
-2607
CY2015Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
1152135 shares
CY2016Q3 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
2257432
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3315555
CY2016Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
38432
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-5876243
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8860664
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5776962
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
318
CY2016Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
8876000 shares
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2461407
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
222959570 shares
CY2016Q3 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
336649
CY2016Q3 pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
167743
CY2016Q3 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
53500 shares
CY2016Q3 pvct Public Offering Issuance Expense
PublicOfferingIssuanceExpense
436248

Files In Submission

Name View Source Status
0001193125-16-764315-index-headers.html Edgar Link pending
0001193125-16-764315-index.html Edgar Link pending
0001193125-16-764315.txt Edgar Link pending
0001193125-16-764315-xbrl.zip Edgar Link pending
d233753d10q.htm Edgar Link pending
d233753dex311.htm Edgar Link pending
d233753dex312.htm Edgar Link pending
d233753dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pvct-20160930.xml Edgar Link completed
pvct-20160930.xsd Edgar Link pending
pvct-20160930_cal.xml Edgar Link unprocessable
pvct-20160930_def.xml Edgar Link unprocessable
pvct-20160930_lab.xml Edgar Link unprocessable
pvct-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending